Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    Scorr-Insert
    X

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    A collaboration with SCORR Marketing

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              eTheRNA immunotherapies

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              BELGIUM Belgium

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              BIO International Convention

              Participation Not Confirmed

              Update your events

              eTheRNA Launches an International Consortium and Starts Development of Cross-strain Protective CoV-2 mRNA Vaccine

              Contact the Supplier

              Lead Product(s): mRNA vaccine

              Therapeutic Area: Infections and Infectious Diseases

              Highest Development Status: Preclinical Product Type: Vaccine

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 24, 2020

              Details:

              The new vaccine is intended specifically for populations at high risk. It is also planned to guard against potential viral mutations by targeting conserved epitopes of the entire CoV-2 genome.

              Ziphius Therapeutics

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              BELGIUM Belgium

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              BIO International Convention

              Participation Not Confirmed

              Update your events

              Ziphius Therapeutics Announces Acceleration of mRNA Based Vaccine Development for COVID-19

              Contact the Supplier

              Lead Product(s): ZIP-1642

              Therapeutic Area: Infections and Infectious Diseases

              Highest Development Status: Preclinical Product Type: Vaccine

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 20, 2020

              Details:

              ZIPHIUS Therapeutics has prioritized its resources to intensify the development of ZIP-1642, a vaccine against the novel coronavirus.

              PharmaCompass__DigitalAd